Trials / Terminated
TerminatedNCT05352542
GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma
A Phase I Clinical Trial for Evaluating the Safety, Tolerance and Efficacy of GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- jianming xu · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A Phase I Clinical Trial for Evaluating the Safety, Tolerance and Efficacy of GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma
Detailed description
This is an open-label, dose escalation/expansion study to assess the safety, tolerability, and efficacy of CART cell in patients ≥ 18 years of age with relapsed or refractory advanced hepatocellular carcinoma. Patients who meet the eligibility criteria will receive cell infusion. The study will include the following sequential phases: screening, pre-treatment (cell product preparation; lymphodepleting chemotherapy), treatment and follow up
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GPC3 Targeting CART Cells | before treatment with GPC3 Targeting CART cells, subjects will receive a conditioning regimen |
Timeline
- Start date
- 2022-05-19
- Primary completion
- 2024-07-31
- Completion
- 2024-07-31
- First posted
- 2022-04-29
- Last updated
- 2024-08-09
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05352542. Inclusion in this directory is not an endorsement.